Ocular's Axpaxli Beats Eylea in Trial — But Is It Enough to Win Over a Skeptical Market?

Ocular Therapeutix's (OCUL) Axpaxli outperformed a low dose of Regeneron's Eylea in a late-stage wet AMD trial — but narrower-than-expected margins sent shares crashing 27%, raising serious doubts about its commercial future.